Glucose Monitoring in Youth With Cystic Fibrosis During Pulmonary Exacerbations

Launched by UNIVERSITY OF COLORADO, DENVER · Aug 6, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how blood sugar levels, also known as glucose levels, are affected in young people with cystic fibrosis (CF) during episodes of lung infections called pulmonary exacerbations. Researchers will use a device called continuous glucose monitoring (CGM) to check these levels in participants both at home and in the hospital. The goal is to see how common issues with blood sugar, known as dysglycemia, are during these health challenges.

To be eligible for this study, participants need to be between 6 and 25 years old and have a confirmed diagnosis of cystic fibrosis. They should also have access to a smartphone or the internet to participate in remote check-ins. However, individuals with certain conditions, such as known diabetes or those who are critically ill or pregnant, cannot join the study. If you choose to participate, you can expect to wear a small device that monitors your glucose levels, and you will be asked to attend virtual visits to discuss your health. This trial aims to improve understanding and management of glucose levels in young people with CF during difficult times.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 6- 25 years old
• • Confirmed diagnosis of cystic fibrosis (based on sweat chloride and/or two known disease causing CF mutations)
• • access to a smart phone and/or internet connection and the ability to complete remote telehealth visits
• Exclusion Criteria:
• • known type 1 or type 2 diabetes, monogenic diabetes
• • critical illness requiring admission to the ICU
• • pregnancy